Bactolife receives USD 5 million in new funding to address gastrointestinal infections worldwide
Summary
The Bill & Melinda Gates Foundation is investing to accelerate Bactolifes mission of developing effective and affordable food and feed ingredients to combat some of the largest gut health issues worldwide.COPENHAGEN, Denmark, Aug. 30, 2022 /PRNewswire/ -- Bactolife today announced that the Bill & Melinda Gates Foundation has committed, in alignment with the foundations charitable mission, an investment of USD 5 million to accelerate the impact of Bactolifes technology platform to develop Binding Proteins, a novel biologic solution to reduce the risk of gut infections in humans and animals.Mads Laustsen, CEO at Bactolife, commented: "With this investment, Bactolife is able to boost our efforts in our technology platform, allowing us to reach our end customers faster and with affordable products that can benefit the many thereby potentially impacting millions of peoples lives worldwide. "Sebastian S\xf8derberg, Deputy CEO at Bactolife, added: "We are proud of and humble for the confidence the Bill & Melinda Gates Foundation has shown us. With Bactolifes technology platform and the investment made by the Bill & Melinda Gates Foundation, Binding Proteins can be formulated into food and feed products, making them easy to ingest.Bactolife is a growing company in the field of gut microbiome health in the food and feed industry. Its proprietary platform consists of a technology for selecting and producing Binding Proteins without targeting growth or killing the bacteria directly. Binding Proteins are stable and highly cost-effective and can be produced at a large scale using leading-edge systems for biomanufacturing.Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.